Lipid Nanoparticle–mRNA Vaccines for Infectious Diseases: Making a Potent Platform Predictable
Vaccines · 19.11.2026 · 14 (11) · 998
DOI: 10.3390/vaccines14110998 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 19.11.2026. Verfasst von Yunwang Zhao und 6 weiteren Autor:innen. Die Arbeit nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Lipid nanoparticle (LNP)–mRNA vaccines compressed the path from pathogen sequence to licensed product into less than a year and are now approved for three viral diseases (COVID-19, respiratory syncytial virus and seasonal influenza), with more than twenty indications in clinical development. The platform’s potency is no longer in doubt; its predictability is. We argue that progress is now limited by three interfaces that are engineered largely independently: the lipid–RNA interface, which sets encapsulation, internal structure and storage stability; the particle–cell interface, which sets tropism and the efficiency of endosomal escape; and the particle–immune interface, which sets the balance between adjuvanticity and reactogenicity. Quantitative design rules exist for the first interface, remain empirical for the second, and are almost absent for the third, which is why formulation development still proceeds by screening rather than by calculation. We review the molecular design of the mRNA payload and structural antigen selection; the chemistry, manufacture and intracellular trafficking of LNPs; the immunological chain that links innate activation and dendritic-cell cross-presentation to germinal-centre output; and the clinical evidence across COVID-19, respiratory syncytial virus, influenza, cytomegalovirus, HIV, personalised cancer vaccines and other targets. We conclude by identifying the measurements, pharmacopoeial quality attributes and design rules that would make the next generation of LNP–mRNA vaccines predictable rather than empirical.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhao, Y., Cheng, H., Zhou, S., He, L., Xiu, C., Huang, B., & Lu, X. (2026). Lipid Nanoparticle–mRNA Vaccines for Infectious Diseases: Making a Potent Platform Predictable. Vaccines, 14(11), 998. https://doi.org/10.3390/vaccines14110998
Vancouver
Zhao Y, Cheng H, Zhou S, He L, Xiu C, Huang B, et al. Lipid Nanoparticle–mRNA Vaccines for Infectious Diseases: Making a Potent Platform Predictable. Vaccines. 2026;14(11):998. doi:10.3390/vaccines14110998
BibTeX
@article{Zhao2026,
author = {Zhao, Yunwang and Cheng, Hongxian and Zhou, Shiyi and He, Lei and Xiu, Chenlin and Huang, Baihai and Lu, Xiongxiong},
title = {Lipid Nanoparticle–mRNA Vaccines for Infectious Diseases: Making a Potent Platform Predictable},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {11},
pages = {998},
doi = {10.3390/vaccines14110998}
}
EUVIMED